Hereditary Alpha-Tryptasemia · TPSAB1 Copy Number Gain · ~5% of Americans
One Gene. Six Systems.
Zero Diagnoses.
HαT drives chronic neuroinflammation across every major organ system — yet no FDA-cleared diagnostic exists
Root Cause
TPSAB1
Extra α-tryptase copies → chronically elevated basal serum tryptase → PAR-2 activation
Overproduction
Excess α-tryptase released constitutively
→
Heterotetramers
α/β hybrid proteins activate PAR-2 with higher potency
→
Cascade
TNF-α, IL-6, IFN-γ · BBB breakdown · Organ inflammation
🧠
Neurological
ADHD, ASD & Neuroinflammation
  • ADHD & ASD features
  • Stimulant non-response
  • Brain fog & sensory dysfunction
  • Anxiety & cognitive impairment
  • Memory impairment (59–68% of symptomatic patients)
✓ Established mechanism
❤️
Autonomic / Cardiovascular
Dysautonomia, POTS & Cardiac Risk
  • Postural orthostatic tachycardia
  • Lightheadedness & syncope
  • Temperature dysregulation
  • Heart rate instability
  • Vasospastic angina — first HαT case 2025
  • Cardiovascular, pain & neuropsychiatric symptoms confirmed (Koch et al., Blood 2025)
✓ Documented in cohorts ⚡ Cardiac risk — new 2025
🫙
Gastrointestinal
Gut-Brain Axis Disruption
  • IBS-like symptoms (3–5× general pop.)
  • Chronic abdominal pain & bloating
  • Celiac disease (~5% vs 0.9% general pop.)
  • Persistent symptoms despite GFD
✓ 2026 peer-reviewed
🦴
Musculoskeletal
Connective Tissue & Autoimmune
  • Joint hypermobility
  • Retained primary dentition
  • Dysphagia
  • SLE, Hashimoto's association
✓ n=266 cohort study
🩸
Metabolic — NEW
Type 2 Diabetes & Insulin Resistance
  • Mast cells directly cause T2DM in animals
  • IL-6 & IFN-γ identical to HαT mediators
  • Tryptase elevated in T2DM pancreatic tissue
  • Mast cell stabilizers reversed T2DM
⚡ Hypothesis — unstudied in HαT
🍷
Addiction — NEW
Alcohol Use Disorder & Withdrawal
  • MRGPRX2 drives withdrawal headache
  • HαT upregulates MRGPRX2 in gut
  • Heavy drinking suppresses tryptase (diagnostic hazard)
  • Mast cell stabilizers may ease withdrawal
⚡ Two-step inference — testable
1 in 20
Americans carry HαT
0
FDA-cleared diagnostics
$300B+
Spent annually on ASD/ADHD treatment
2024
First validated ddPCR assay
Prepared by Sarah Anderson · Tryptase Place · April 2026 · All mechanisms sourced from peer-reviewed literature
From Gene to Disease — The HαT Cascade
How One Gene Duplication
Drives Six Chronic Conditions
The same PAR-2 pathway operating in the brain operates identically in metabolic and addiction biology
🧬
Step 1 · Genetic Root
TPSAB1 Copy Number Gain
Extra copies of TPSAB1 on a single chromosome produce chronically elevated alpha-tryptase. The more copies, the higher the tryptase — and the more severe the downstream inflammation. Affects ~5% of the Western population. Invisible to standard genetic testing.
⚗️
Step 2 · Molecular Activation
α/β Heterotetramer Formation & PAR-2 Activation
Excess alpha-tryptase forces assembly of hybrid α/β tetramers that activate PAR-2 with far greater potency than normal tryptase. PAR-2 and EMR2 are expressed throughout the brain vasculature, gut wall, dural mast cells, and vascular endothelium (Koch et al., Blood 2025).
🔥
Step 3 · Inflammatory Cascade
TNF-α · IL-6 · IFN-γ · MMP-2/9
PAR-2 triggers sustained release of TNF-α and IL-6 via NFκB/p38 pathways, degrades the blood-brain barrier via MMP-2/MMP-9, and sensitizes MRGPRX2 on mast cells throughout the gut and dura mater.
🧠
Step 4a · Brain & Nervous System
Blood-Brain Barrier Breakdown & Neuroinflammation
BBB disruption lets systemic cytokines flood the CNS. Mast cell–microglia interactions sustain neuroinflammation in ADHD, ASD, and epilepsy (Biomolecules, April 2026). Dopamine transporter function is impaired — stimulants cannot fix what they cannot reach.
ADHD ASD Anxiety Alzheimer's risk
❤️
Step 4b · Cardiovascular — NEW 2025
Vascular Endothelium & Cardiac Risk
PAR-2 and EMR2 activation on vascular endothelium extends HαT symptom spectrum to cardiovascular, pain, and neuropsychiatric symptoms (Koch et al., Blood 2025). First published HαT vasospastic angina case: treatment-resistant coronary disease controlled by antihistamine after HαT diagnosis (Caullery et al., Eur Heart J Case Rep, March 2025).
Vasospastic angina Cardiac risk Vascular inflammation
🫙
Step 4c · Gut-Brain Axis
MRGPRX2 Upregulation & Gut Mast Cell Sensitization
PAR-2 upregulates MRGPRX2 in enteric mast cells (confirmed 2026, Frontiers in Allergy, n=854). The gut becomes a continuous source of systemic tryptase and a sensitized site for alcohol-withdrawal mast cell degranulation.
IBS Celiac modifier IBD modifier GLP-1 disruption
🩸
Step 4d · Metabolic System — NEW
Adipose Mast Cell Activation → Insulin Resistance
IL-6 and IFN-γ from primed mast cells drive insulin resistance and T2DM — demonstrated causally in two strains of mast cell–deficient mice. Tryptase and histamine are overexpressed in T2DM pancreatic tissue.
Insulin resistance T2DM risk Beta cell stress
🍷
Step 4e · Addiction Biology — NEW
Dural MRGPRX2 → Withdrawal Amplification → Relapse
Alcohol withdrawal activates dural mast cells via MRGPRX2/MrgprB2, causing the severe headaches that drive rehabilitation failure (Neuron, 2023). HαT already upregulates MRGPRX2. Heavy drinking also suppresses serum tryptase, masking HαT diagnosis in active drinkers.
Withdrawal severity Relapse risk Diagnostic masking
Scientific Evidence Assessment · April 2026
What We Know vs.
What Must Be Studied
Established in peer-reviewed literature
Biologically plausible — untested in HαT
Direct study does not yet exist
🧠
Neurological
ADHD · ASD · Neuroinflammation
Mast cell–microglia link confirmed in ADHD, ASD & epilepsy (Biomolecules, April 2026)
PAR-2 tryptase inhibition reduces neuroinflammation and hippocampal neurodegeneration (J Neuroinflammation, 2020)
Memory impairment documented in 59–68% of symptomatic HαT patients
Stimulant failure rate in HαT-positive children — mechanistically predicted, not yet measured
Lyons et al. Nat Genet 2016; Ocak et al. J Neuroinflammation 2020; Biomolecules 16(4):530, 2026
🫙
Gastrointestinal
IBS · Celiac · IBD · Gut-Brain Axis
MRGPRX2 upregulated in HαT intestinal mast cells (Galeas-Pena et al., Frontiers in Allergy 2026, n=854)
IBS prevalence 3–5× higher in elevated tryptase populations
Celiac disease ~5% in HαT cohorts vs. 0.9% general population; persistent GI symptoms despite GFD
HαT confirmed as GI disease modifier (Simeone et al., Frontiers in Allergy 2026)
Simeone et al. Front Allergy 2026; Galeas-Pena et al. Front Allergy 2026
❤️
Autonomic / Cardiovascular
POTS · Vasospastic Angina · Anaphylaxis
HαT independently increases anaphylaxis incidence and severity — confirmed modifier of mast cell disease
HαT extends to cardiovascular, pain and neuropsychiatric symptoms via PAR-2 and EMR2 on vascular endothelium (Koch et al., Blood 2025)
First HαT vasospastic angina case — treatment-resistant coronary disease controlled by antihistamine after HαT diagnosis (Caullery et al., Eur Heart J Case Rep, March 2025)
POTS prevalence in HαT — earlier associations not fully replicated; ongoing research
Koch et al. Blood 2025; Caullery et al. Eur Heart J Case Rep 2025; Condoluci et al. Swiss Med Weekly 2025
🔬
Alzheimer's
Neurodegeneration · Cognitive Decline
Masitinib (mast cell inhibitor) slowed Alzheimer's cognitive decline in Phase 3 RCT — –2.15 ADAS-cog vs. placebo (Dubois et al., 2023)
Amyloid-β triggers mast cell degranulation; mast cell products drive microglia-mediated neurotoxicity
PAR-2/BBB disruption is a hallmark of early Alzheimer's pathology — identical to HαT mechanism
HαT prevalence in Alzheimer's cohorts — never measured
Dubois et al. Alzheimers Res Ther 2023; Kothari et al. Cell 2025
🩸
Type 2 Diabetes — NEW
Insulin Resistance · Beta Cell Stress
Mast cell deficiency prevents T2DM in two mouse strains; MC transfer restores it (Liu et al., Nat Med 2009)
IL-6 and IFN-γ causally required for diet-induced T2DM — same cytokines HαT produces via PAR-2
Tryptase elevated in obese humans (p=0.008); overexpressed in T2DM pancreatic tissue
HαT prevalence in T2DM cohorts — no study exists
Liu et al. Nat Med 2009 (PMC3341969); Wang et al. 2012 (PMC3318912)
🍷
Alcohol Use Disorder — NEW
Withdrawal · Relapse · Liver Disease
MRGPRX2/MrgprB2 mediates withdrawal headache via dural mast cell degranulation — absent in receptor-KO mice (Son et al., Neuron 2023)
Heavy drinking reduces serum tryptase — diagnostic hazard: HαT may be missed in active drinkers
HαT MRGPRX2 upregulation confirmed in gut — plausibly extends to dural/CNS mast cells but untested
HαT prevalence in AUD treatment cohorts — never measured
Son et al. Neuron 2023 (PMC10843090); Beceiro et al. Alcohol Clin Exp Res 2015
The Addiction–HαT Connection · Published in Neuron 2023
The Receptor That Links
HαT to Alcohol Relapse
MRGPRX2 — already upregulated in HαT — is the same receptor that drives withdrawal headache and rehabilitation failure
🧬
What HαT Does to MRGPRX2
HαT significantly upregulates MRGPRX2 expression in intestinal mast cells — confirmed by spatial transcriptomics and CyTOF mass cytometry (Galeas-Pena et al., Frontiers in Allergy 2026, n=854). The receptor is sensitised and primed before any alcohol exposure.
🍺
The Diagnostic Trap
Heavy alcohol consumption reduces serum basal tryptase. A patient with 4 TPSAB1 copies drinking heavily daily may test below the 8 ng/mL threshold — and be told they don't have HαT. The ddPCR assay is unaffected by this confound.
🏥
Gut → Liver Pathway
Alcohol disrupts gut microbiota and directly boosts mast cell activation. In HαT, with constitutively primed mast cells and elevated tryptase, alcohol-induced liver injury may accelerate at lower consumption levels.
🔴
MRGPRX2
Mast cell receptor
The pivot point
🍷
What Alcohol Withdrawal Does
Alcohol withdrawal activates MRGPRX2/MrgprB2 on dural mast cells, triggering degranulation and trigeminal neuron sensitisation — causing severe headache. Mice lacking this receptor had zero withdrawal headache behaviours. (Son et al., Neuron 2023)
🔄
The Relapse Cycle
Withdrawal pain → drink to relieve pain → pain relief reinforces drinking → dependence deepens. In HαT, MRGPRX2 is already upregulated. More severe withdrawal pain = stronger drive to resume drinking. Biology, not willpower.
💊
The Testable Treatment
Mast cell stabilisers (cromolyn, ketotifen) — already used off-label in HαT — directly target the mechanism. Testing whether they reduce withdrawal severity is actionable today.
⚠️
The key insight for clinicians: If a patient presents for alcohol use disorder assessment, standard BST screening for HαT may be falsified by their drinking. Always use ddPCR TPSAB1 copy number analysis in active drinkers — it is not affected by alcohol-induced tryptase suppression. HαT may be driving both the disorder and the diagnostic invisibility simultaneously.
The Scientific Emergency — April 2026
What We Know vs.
What We're Missing
The mechanism is established. The population is identifiable. The tools exist. The studies have not been done.
✓ What Is Already Established
1
Mast cells directly cause T2DM
Two strains of MC-deficient mice failed to develop diet-induced diabetes. MC transfer restored it. Cromolyn and ketotifen reversed pre-established T2DM.
Liu et al., Nat Med 2009
2
MRGPRX2 mediates withdrawal headache
MrgprB2-deficient mice showed zero withdrawal headache behaviours. Dural mast cell degranulation was entirely receptor-dependent.
Son et al., Neuron 2023
3
HαT upregulates gut MRGPRX2
Spatial transcriptomics and CyTOF confirmed significantly increased MRGPRX2 expression in HαT intestinal mast cells (n=854 IBD biobank).
Galeas-Pena et al., Front Allergy 2026
4
Heavy drinking suppresses serum tryptase
Active heavy drinkers may have BST below the 8 ng/mL HαT threshold — causing false negatives. ddPCR is unaffected.
Beceiro et al., Alcohol Clin Exp Res 2015
5
Masitinib slowed Alzheimer's in Phase 3 RCT
First successful Phase 3 AD trial targeting innate immune cells rather than amyloid. Benefit specifically mast-cell mediated (–2.15 ADAS-cog, p<0.001).
Dubois et al., Alzheimers Res Ther 2023
6
HαT confirmed as cardiac risk modifier
First published HαT vasospastic angina case — treatment-resistant coronary disease controlled by antihistamine. HαT confirmed to extend to cardiovascular and neuropsychiatric symptom domains via PAR-2/EMR2.
Caullery et al., Eur Heart J Case Rep 2025; Koch et al., Blood 2025
7
Tryptase overexpressed in T2DM pancreatic tissue
Histamine and tryptase genes overexpressed in mast cells within pancreatic islets of T2DM patients. MC infiltration correlates with beta cell damage.
PubMed 28155967; PMC7547971
✕ What Has Never Been Studied
1
HαT prevalence in T2DM cohorts
No study has measured TPSAB1 copy number in a diabetic population. No study has collected HbA1c or HOMA-IR from HαT registries.
Proposed: ddPCR in UK Biobank or VA T2DM registry
2
HαT prevalence in AUD treatment cohorts
No study has tested TPSAB1 copy number in alcohol use disorder populations or correlated it with withdrawal severity or relapse rates.
Proposed: ddPCR in AUD treatment registries
3
Mast cell stabilisers for alcohol withdrawal
No trial has tested cromolyn or ketotifen for reducing withdrawal severity or relapse rates. The Son et al. mechanism makes this directly actionable.
Proposed: RCT in AUD patients on mast cell stabilisers
4
MRGPRX2 in dural/CNS mast cells in HαT
Gut upregulation is confirmed. Whether it extends to the dural tissue implicated in withdrawal headache is unknown — the critical mechanistic step for the AUD hypothesis.
Proposed: Biopsy/autopsy tissue study in HαT subjects
5
HαT as cardiac risk modifier — population level
The Caullery 2025 case is a single patient. Whether HαT-positive individuals have elevated rates of vasospastic cardiac events — potentially explaining premature cardiac death in young adults — has never been studied in a cohort.
Proposed: Retrospective ddPCR genotyping in sudden cardiac death registries
6
HαT in Alzheimer's cohorts
No study has measured TPSAB1 copy number in AD patients. Memory impairment in 59–68% of symptomatic HαT patients has never been followed longitudinally.
Proposed: Retrospective ddPCR genotyping in masitinib trial samples
7
Treatment-resistant ASD/ADHD prevalence
No large-scale ddPCR prevalence study has been done in treatment-resistant ASD or ADHD cohorts. This is the central policy ask — and the most fundable.
Proposed: NIH/ARPA-H grant, n=2,000+, ddPCR methodology
The Tools Exist. The Studies Do Not.
ddPCR TPSAB1 genotyping was validated in 2024. The NIH HαT cohort already exists. Every unstudied gap above is actionable within 12–18 months with existing infrastructure.
7
Established findings
7
Unstudied gaps
$0
New drugs needed